Assembly Biosciences, Inc.: 10-Q filed 2017-05-08

Name: Assembly Biosciences, Inc.: 10-Q filed 2017-05-08
Creator: Assembly Biosciences, Inc.

What Assembly Biosciences, Inc. reported in its quarterly report filed 2017-05-08 (fiscal Q1 2017): 27 published measures, 56 facts as tagged in accession 0001144204-17-024996.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-05-08
Fiscal period: fiscal Q1 2017
Accession: 0001144204-17-024996 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Assembly Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-03-31	134,284,191	USD
At 2016-12-31	98,118,606	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-03-31	66,396,027	USD
At 2016-12-31	18,240,605	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-03-31	67,888,164	USD
At 2016-12-31	79,878,001	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-03-31	70,818,011	USD
At 2016-12-31	28,575,085	USD
At 2016-03-31	20,395,045	USD
At 2015-12-31	27,107,526	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-13,930,593	USD	90
2016-01-01 to 2016-03-31	-10,988,558	USD	91

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	0	USD	90
2016-01-01 to 2016-03-31	2,163	USD	91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-03-31	-222,158,060	USD
At 2016-12-31	-208,227,467	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-03-31	182,771	USD
At 2016-12-31	214,687	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	1,224,647	USD	90
2016-01-01 to 2016-03-31	1,459,855	USD	91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-13,929,829	USD	90
2016-01-01 to 2016-03-31	-11,277,152	USD	91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-03-31	92,221,684	USD
At 2016-12-31	53,574,664	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-03-31	10,956,639	USD
At 2016-12-31	7,120,954	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2017-03-31	12,638,136	USD
At 2016-12-31	12,638,136	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	10,573,739	USD	90
2016-01-01 to 2016-03-31	8,118,576	USD	91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-03-31	17,318,044	shares
At 2016-12-31	17,246,754	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-03-31	290,553,583	USD
At 2016-12-31	288,688,990	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2017-03-31	-524,677	USD
At 2016-12-31	-600,769	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2017-03-31	409,285	USD
At 2016-12-31	409,285	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2017-03-31	226,514	USD
At 2016-12-31	194,598	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2017-03-31	29,000,000	USD
At 2016-12-31	29,000,000	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2017-03-31	4,013,562	USD
At 2016-12-31	4,752,823	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2017-03-31	1,298,673	USD
At 2016-12-31	611,176	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-13,854,501	USD	90
2016-01-01 to 2016-03-31	-10,916,468	USD	91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	4,040,459	USD	90
2016-01-01 to 2016-03-31	3,158,576	USD	91

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	31,916	USD	90
2016-01-01 to 2016-03-31	18,558	USD	91

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-764	USD	90
2016-01-01 to 2016-03-31	288,594	USD	91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-420,948	USD	90
2016-01-01 to 2016-03-31	962,450	USD	91

Inspect the source

Entity: Assembly Biosciences, Inc. / CIK 0001426800
Captured: 2026-09-20T08:03:55.156Z
SEC response SHA-256: f87ee3d44f43bd73d30c280e8d97b2de4bcc4d8a35b03fbebb0e715c83069335

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001426800.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))